Free Cash Flow (Quarterly) Chart

Historical Free Cash Flow (Quarterly) Data

View and export this data back to 2000. Start Trial.
Date Value
June 30, 2026 -95.09M
March 31, 2026 -226.22M
December 31, 2025 -294.18M
September 30, 2025 -222.18M
June 30, 2025 -209.05M
March 31, 2025 -272.16M
December 31, 2024 -202.75M
September 30, 2024 -184.60M
June 30, 2024 -129.74M
March 31, 2024 -188.71M
December 31, 2023 -131.75M
September 30, 2023 -139.19M
June 30, 2023 -127.68M
March 31, 2023 -150.92M
December 31, 2022 -107.84M
September 30, 2022 -90.41M
June 30, 2022 -105.20M
March 31, 2022 -106.86M
December 31, 2021 -85.27M
September 30, 2021 -76.93M
June 30, 2021 -78.93M
March 31, 2021 -129.46M
December 31, 2020 -67.72M
September 30, 2020 -59.42M
June 30, 2020 -37.83M
Date Value
March 31, 2020 -60.61M
December 31, 2019 -57.44M
September 30, 2019 -66.96M
June 30, 2019 -90.64M
March 31, 2019 -77.88M
December 31, 2018 -72.56M
September 30, 2018 -67.34M
June 30, 2018 -57.76M
March 31, 2018 -73.40M
December 31, 2017 -49.92M
September 30, 2017 -38.68M
June 30, 2017 -36.68M
March 31, 2017 -37.33M
December 31, 2016 -58.73M
September 30, 2016 -32.28M
June 30, 2016 -29.78M
March 31, 2016 -30.12M
December 31, 2015 -27.95M
September 30, 2015 -24.88M
June 30, 2015 -25.17M
March 31, 2015 -26.15M
December 31, 2014 -14.47M
September 30, 2014 -23.82M
June 30, 2014 -18.49M
March 31, 2014 -12.98M

Free Cash Flow Definition

Free Cash Flow is the cash a company has left after paying for its day-to-day operations and investing in its physical assets, such as buildings, equipment and technology. The company can use that cash however it chooses: paying dividends, buying back shares, paying down debt, making acquisitions or keeping it for future growth.

Read full definition.

Free Cash Flow (Quarterly) Range, Past 5 Years

View Free Cash Flow (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Free Cash Flow (Quarterly) Benchmarks

View Free Cash Flow (Quarterly) Benchmarks
Start Trial
ACADIA Pharmaceuticals, Inc. 95.69M
Biogen, Inc. 308.00M
Gilead Sciences, Inc. 3.433B
United Therapeutics Corp. 202.20M
Vertex Pharmaceuticals, Inc. 1.013B